Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

I’ve heard that trauma doesn’t make people stronger, and I’ve found that after cancer, I’m not the same person that I was before. Even if care teams have all of your information on their end, ...

A look at the treatment courses for the follicular lymphoma form of non-Hodgkin's lymphoma.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Liso-cel, a CD19-directed chimeric antigen receptor T-cell product, and mosunetuzumab, a CD20/CD3 bispecific antibody, are used to treat patients with relapsed/refractory follicular lymphoma.

Distinction between atypical lymphoid proliferations with follicular pattern and follicular ... significant lymphadenopathy – that is, lymph nodes >2 cm in size – organomegaly (hepatomegaly ...

In the Mithic-FL1 trial, patients with newly diagnosed high-burden follicular lymphoma (FL) demonstrated complete response (CR) rates of 80% and manageable adverse events with outpatient ...

T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

They may be lymphocytic cells or come from other lines of blood cells. Lymphocytes are produced in the bone marrow but after release are found throughout the lymphatic system (such as in the lymph ...

Symptoms of MCL are similar to those of many other types of non-Hodgkin’s lymphoma and may include one or more of the following: Painless, swollen lymph nodes Fevers and night sweats Unintentional ...

Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma.